معلومات عن هذه الحلقة
Blackstone commits up to 1.5 billion dollars to Pfizer's monthly obesity shot berobenatide, and Reuters reports the FDA has shelved its Commissioner's National Priority Voucher program. Also: FDA staffing gaps, a Bristol Myers Squibb R&D overhaul, Windward Bio's 175 million dollar IPO and a 105 million dollar Series B for Neurosterix.
Good morning from Pharma and Biotech Daily, the briefing on what matters in pharma and biotech. It's Friday, November 13.
Today, private equity puts up serious money behind a Pfizer obesity drug, and a report says the FDA has quietly parked its fast track voucher program.
We start with Pfizer. Blackstone Life Sciences will provide up to one point five billion dollars to help fund berobenatide, a potential once a month G L P one injection that Pfizer gained through its roughly ten billion dollar purchase of Metsera. BioPharma Dive reports the money arrives in phases through 2028 and supports as many as ten Phase three trials. Pfizer pays Blackstone milestones only if the FDA approves the drug as a monthly single agent for weight management and sales targets are met. The deal matters because it shifts part of the cost of a very large obesity program off Pfizer's books, just as generic competition for Eliquis and Ibrance starts to weigh on earnings.
Next, Washington. BioSpace, citing Reuters, reports that the FDA has effectively shelved the Commissioner's National Priority Voucher program launched by former commissioner Marty Makary. Companies can still apply, but according to six people quoted by Reuters, those applications are not moving forward. Twenty two drugs received a voucher and twelve have been approved, yet none have been awarded since Makary left in May. An FDA spokesperson says the pilot is ongoing and career staff continue to review applications. Holders such as Compass Pathways now face more timeline uncertainty, while the Senate committee vote on commissioner nominee Heidi Overton is set for November 18.
Staying with the agency, a separate BioPharma Dive analysis finds the FDA's drug and biologics centers had one thousand three hundred forty three fewer employees in September than two years earlier. Hiring is slow, and companies report that informal feedback from reviewers is harder to get. That can mean extra meetings and pre submissions, adding time and cost. Lawyers who advise drugmakers expect rebuilding the workforce to take a year or two. The practical message for development teams is to plan regulatory timelines with more slack, especially at smaller companies with less cash to absorb delays.
At Bristol Myers Squibb, research chief Robert Plenge is leaving, and the company is combining research and development into a single organization. Chief medical officer Cristian Massacesi becomes head of R and D on January first, while Plenge stays through March to help with the handover. BioPharma Dive notes the company says the change will speed decisions and sharpen portfolio management. It comes as Eliquis, which brought in more than fourteen billion dollars last year, heads toward patent expiry, and after recent setbacks including a failed Camzyos study.
In capital markets, Swiss immune drug developer Windward Bio priced a one hundred seventy five million dollar IPO, selling shares at seventeen dollars, with trading set to begin today under the ticker W W B. Sanofi is buying another fifty million dollars in a private placement. Windward's lead drug, WIN three seventy eight, targets the same protein as Tezspire but could be given as rarely as twice a year. Both of its programs were licensed from Chinese companies. BioPharma Dive counts this as the sector's thirtieth IPO of the year, which makes 2026 the busiest year for drugmaker listings since 2021.
Finally, private funding. BioSpace reports that Neurosterix, a spinout of Swiss biotech Addex Therapeutics, raised a one hundred five million dollar Series B led by RTW Investments, with GV and Janus Henderson also taking part. The money will move NTX two fifty three, an oral drug that modulates the M four muscarinic receptor, into Phase two testing in schizophrenia. The company has added several Karuna veterans to its board and clinical advisory ranks. The round is up sharply from its sixty three million dollar Series A in 2024, a sign that investors still want exposure to the muscarinic approach to psychosis, which aims to avoid the movement and metabolic side effects of older antipsychotics.
The thread running through today is capital and capacity: money is finding its way to late stage and well understood bets, while the regulator that ultimately judges them is running thinner and less predictable.
That's the briefing for today. Pharma and Biotech Daily is produced by OWITH.ai. See you on Monday.
Sources:
https://www.biopharmadive.com/news/blackstone-pfizer-berobenatide-deal/874483/
https://www.biospace.com/business/pfizer-snags-1-5b-financing-from-pe-firm-blackstone-to-support-metsera-asset
https://www.biospace.com/fda/fdas-commissioner-voucher-program-reportedly-shuttered-ahead-of-senate-vote-on-overton
https://www.biopharmadive.com/news/fda-staffing-shortages-drug-reviews-pharma/874480/
https://www.biopharmadive.com/news/bristol-myers-robert-plenge-cristian-massacesi-research-transition/874476/
https://www.biospace.com/business/bms-r-d-head-to-depart-amid-restructure
https://www.biopharmadive.com/news/windward-ipo-pricing-immune-drugs-china-deals-tezspire/874533/
https://www.biospace.com/drug-development/neurosterix-nabs-105m-recruits-karuna-veterans-for-schizophrenia-push
Pharma and Biotech Daily is produced by OWITH.ai. Script and voice are AI generated from the public sources listed above. Not medical or investment advice.
الإنجليزية
الولايات المتحدة
في هذه الحلقة
النص 🔗
Are you the producer of this podcast?
Add a podcast transcript
Need Audio-to-Text?
Transcribe with Listen411 in Just 60 Seconds
البحث في الحلقات الماضية
البحث في الحلقات السابقة من Pharma and BioTech Daily.
حلقات أخرى في هذا البودكاست
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into some of the most significant advancements and challenges shaping these dynamic sectors.
In a notable regulatory update, the U.S. Food and Drug A…
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of impactful advancements and strategic shifts shaping the industry landscape.
Cerevance has made headlines with its drug Sole…
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of compelling stories that highlight the dynamic nature of the industry, marked by strategic acquisitions, groundbreaking research, and …
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world.
Today, we're diving into some of the most compelling stories shaping the industry. Let's begin with GSK's bold move to expand its biologics capabiliti…
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of significant advancements and strategic shifts shaping the industry landscape.
We begin with the integration of artificial i…
إخلاء المسؤولية: البودكاست والأعمال الفنية المضمنة في هذه الصفحة مأخوذة من Pharma and BioTech News، وهي مملوكة لمالكها وليست تابعة لشركة Listen Notes, Inc أو معتمدة منها.
تعديل
شكراً على مساعدتنا في الحفاظ على قاعدة بيانات البودكاست مُحدَّثة.